Glide Technologies Announces Successful Proof-of-Concept With Novel Exenatide Solid Dose Formulation

OXFORD, England, January 6, 2016 /PRNewswire/ --

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, today announced that the Company has successfully completed a pre-clinical proof-of-concept study with its novel solid dose formulation of exenatide, a GLP-1 agonist for the treatment of type 2 diabetes.  Results from the pharmacokinetic study show that there was no statistical difference (p<0.05) between Glide's solid dose formulation and the clinical dose of Byetta® (exenatide 10 mcg), the currently marketed liquid product.

Glide's solid dose formulations are designed to be delivered using the Company's self-administered, user-friendly, needle-free SDI® injector. The technology has multiple advantages over currently marketed liquid peptide products, which are needle administered and require cold chain logistics and refrigeration in the home. In particular, the technology has the potential to significantly improve patient compliance, which is important where self-administered injections are required, such as in diabetes.

The results follow previously announced successful proof-of-concept studies with Glide's novel solid dose formulations of currently marketed liquid products Forteo®/Forsteo® (teriparatide) and Sandostatin® (octreotide).  Consequently, Glide's solid dose formulation technology has now achieved equivalence across a series of peptide products, demonstrating the flexibility of the platform to deliver this important class of therapeutics.  

Dr Mark Carnegie-Brown, Glide's CEO, commented, "These encouraging results follow positive equivalence data with Glide's octreotide SDI®and teriparatide SDI®and clearly demonstrate the flexibility of our solid dose technology in delivering therapeutic peptides. The Glide SDI® has important advantages over current liquid products, particularly for self-administered treatments where patient-focused ease-of-use and compliance are key." 

About Glide Technologies 

Glide is a development company focused on solid dose formulations of therapeutics and vaccines.  It has a growing pipeline of products based on its proprietary solid dose injector, the Glide SDI®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines.  Glide's pipeline of solid dose formulations includes octreotide, teriparatide, exenatide and anthrax and influenza vaccines.  

The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors.  Glide Technologies has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.  For more information please visit http://www.glide-technologies.com .

Contacts:
Dr Mark Carnegie-Brown
Chief Executive Officer
Glide Technologies
Tel: +44-(0)1235-577120    

Rob Budge
RJB Communications
Tel: +44-(0)1865-760969
Mobile: +44-(0)7710-741241

SOURCE Glide Technologies